scholarly journals An Australasian perspective on the curative treatment of patients with pancreatic cancer, supportive care, and future directions for management

2016 ◽  
Vol 10 ◽  
Author(s):  
Wendy Muircroft
Keyword(s):  
Pancreatic Cancer ◽  
Supportive Care ◽  
Curative Treatment ◽  
Future Directions

Terpenoids as Potential Targeted Therapeutics of Pancreatic Cancer: Current Advances and Future Directions

2019 ◽  
pp. 111-116 ◽  
Author(s):  
Rama Rao Malla ◽  
Seema Kumari ◽  
K.G.K. Deepak ◽  
Murali Mohan Gavara ◽  
Shailender Guganavath ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Targeted Therapeutics ◽  
Future Directions

scholarly journals MicroRNA in Pancreatic Cancer: From Biology to Therapeutic Potential

Genes ◽  
2019 ◽  
Vol 10 (10) ◽  
pp. 752 ◽  
Author(s):  
Rawat ◽  
Kadian ◽  
Gupta ◽  
Kumar ◽  
Chain ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Therapeutic Potential ◽  
Critical Role ◽  
Mirna Biogenesis ◽  
Effective Management ◽  
Future Directions ◽  
Novel Therapeutic Strategies ◽  
Conclusion Section

Pancreatic cancer is one of the most aggressive malignancies, accounting for more than 45,750 deaths annually in the U.S. alone. The aggressive nature and late diagnosis of pancreatic cancer, coupled with the limitations of existing chemotherapy, present the pressing need for the development of novel therapeutic strategies. Recent reports have demonstrated a critical role of microRNAs (miRNAs) in the initiation, progression, and metastasis of cancer. Furthermore, aberrant expressions of miRNAs have often been associated with the cause and consequence of pancreatic cancer, emphasizing the possible use of miRNAs in the effective management of pancreatic cancer patients. In this review, we provide a brief overview of miRNA biogenesis and its role in fundamental cellular process and miRNA studies in pancreatic cancer patients and animal models. Subsequent sections narrate the role of miRNA in, (i) cell cycle and proliferation; (ii) apoptosis; (iii) invasions and metastasis; and (iv) various cellular signaling pathways. We also describe the role of miRNA’s in pancreatic cancer; (i) diagnosis; (ii) prognosis and (iii) therapeutic intervention. Conclusion section describes the gist of review with future directions.

Breaking immune tolerance for the treatment of pancreatic cancer: Phase I/II clinical experience.

2019 ◽  
Vol 37 (8_suppl) ◽  
pp. 54-54
Author(s):  
David Nam ◽  
Larn Hwang ◽  
Vuong N. Trieu
Keyword(s):  
Pancreatic Cancer ◽  
Liver Metastasis ◽  
Supportive Care ◽  
Immune Tolerance ◽  
Tumor Vaccine ◽  
Complete Response ◽  
Best Supportive Care ◽  
P Values ◽  
Cell Kill

54 Background: Escalating Intratumoral heterogeneity resulting in xenogenization which is countered by overexpression of TGF-β. Here we report on the use of OT-101/Chemo to break immune tolerance to cure pancreatic cancer (PC). OT-101 is an antisense against TGF-β2. Methods: Total of 37 pts 2nd line and beyond received OT-101 with option to go on subsequent Chemo (OT-101/Chemo) or Best Supportive Care (BSC) (OT-101/BSC). Stratification by treatment line, schedule, metastasis location, disease control (DC), and baseline CA19-9, was performed. Plasma levels of 31 cyto-/chemokine were measured in a subset of 12 pts. Results: mOS of the 18 pts receiving OT-101/Chemo was 9.4 mos vs. OT-101/BSC (2.8 mos, p=0.0004). No significance was observed on stratification. However, pts with only liver metastasis had a mOS of 9.5 mos while those with liver metastasis and others only had a mOS of 4.7 mos (p=0.0077). Among the former, 1006 has Complete Response beyond 77.3 mos and 1022 had Stable Disease with OS of 40.3 mos; and OS was higher with OT-101/Chemo – 12.4 mos versus 1.9 mos, p=0.0006. There were 16 of 37 pts with DC, with mOS of 9.7 mos vs. 3.0 mos (p<0.0001); and OS was higher with OT-101/Chemo – 11.8 mos vs. 5.0 mos, p=0.0021. Pts exhibited spike in IL-8 level which returned to basal level at treatment stop. R squares relating the IL-8 spike and OS were 0.8522 and 0.9895 and p values were 0.0011 and 0.0053 for OT-101/Chemo and OT-101/BSC, respectively. Preclinically, OT-101 enhanced PBMC activity in cell kill assay and in vivo xenograft. Conclusions: The MOA for OT-101/Chemotherapy is consistent with the reactivation of immunity during TGF-β suppression and subsequent boosting/expansion of immunity during Chemo. Contrary to traditional tumor vaccine- this is universally applicable to all patients.

scholarly journals Neoadjuvant Therapy in Pancreatic Cancer: An Emerging Strategy

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Alessandro Bittoni ◽  
Matteo Santoni ◽  
Andrea Lanese ◽  
Chiara Pellei ◽  
Kalliopi Andrikou ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Case Series ◽  
Tumour Response ◽  
Tumour Regression ◽  
Resectable Pancreatic Cancer ◽  
Borderline Resectable ◽  
Future Directions ◽  
Tumour Implantation

Pancreatic adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths among men and women, being responsible for 6% of all cancer-related deaths. Surgical resection offers the only chance of cure, but only 15 to 20 percent of cases are potentially resectable at presentation. In recent years, increasing evidences support the use of neoadjuvant strategies in pancreatic cancer in patients with resectable pancreatic cancer as well as in patients with borderline resectable or locally advanced PDAC in order to allow early treatment of micrometastatic disease, tumour regression, and reduced risk of peritoneal tumour implantation during surgery. Furthermore, neoadjuvant treatment allows evaluation of tumour response and increases patient’s compliance. However, most evidences in this setting come from retrospective analysis or small case series and in many studies chemotherapy or chemoradiation therapies used were suboptimal. Currently, prospective randomized trials using the most active chemotherapy regimens available are trying to define the real benefit of neoadjuvant strategies compared to conventional adjuvant strategies. In this review, the authors examined available data on neoadjuvant treatment in patients with resectable pancreatic cancer as well as in patients with borderline resectable or locally advanced PDAC and the future directions in this peculiar setting.

Sign in / Sign up

Export Citation Format

Share Document